Next Quarterly Earnings
Tuesday, November 10, 2026
CW 46
Pre-Market
In 75 days
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
Supernus Pharmaceuticals
Supernus Pharmaceuticals develops and commercializes innovative therapies for central nervous system disorders. The company focuses on neurology and psychiatry to offer high-quality treatment options for patients with complex CNS conditions. Its core activities include research, development, and marketing of new medications aimed at improving quality of life.
Frequently asked questions
When will Supernus Pharmaceuticals report its next quarterly earnings?
Supernus Pharmaceuticals is scheduled to report its next quarterly earnings on 11/10/2026. Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
When did Supernus Pharmaceuticals last report quarterly earnings?
Supernus Pharmaceuticals last reported quarterly earnings on 8/3/2026 (Q2 2026). Earnings per share (EPS) came in at 0.53 USD.
How does Supernus Pharmaceuticals stock react to earnings?
Across its last 3 earnings reports, Supernus Pharmaceuticals stock moved by ±9.2% on average the following day. The largest reaction was -17.4% on 11/04/2025; 2 of 3 reactions were positive.
How often has Supernus Pharmaceuticals beaten expectations?
Supernus Pharmaceuticals has beaten analyst EPS estimates in 4 of its last 5 evaluated quarters (beat rate: 80%).
How do I add the Supernus Pharmaceuticals earnings dates to my calendar?
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
All Dates
Earnings statistics
Stock reaction to earnings
±9.2%
Avg. next-day move
-17.4%
Largest move (11/04/2025)
66.7%
Share of positive reactions
±8.1%
Avg. move after 7 days
Basis: price reactions to the last 3 report dates (close to close).
Estimates vs. results
4/5
Quarters above estimates
80%
Beat rate
+77.1%
Avg. EPS surprise
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.
Company Information
Name
Supernus Pharmaceuticals
Country
🇺🇸
More Financial Information